Evidence map›Paper›PMID 41402766›Full record

ArticleBMC nephrology2025

Risk factors for short-term mortality in elderly critically ill AKI patients treated with CRRT in the ICU: a retrospective cohort study.

Xiaoling Zhang, Yajing Li, Shuting Feng

Abstract read
In one paragraph

Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Xiaoling ZhangDepartment of Blood Purification, Jinqiu Hospital of Liaoning Province, Shenyang, China.
Yajing LiNephrology Department, Jinqiu Hospital of Liaoning Province, Shenyang, China.
Shuting FengJinqiu Hospital of Liaoning Province, No. 317, Xiaonan Street, Shenyang, 110122, China. shuting_feng@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundContinuous renal replacement therapy (CRRT) is important for elderly critically ill patients with acute kidney injury (AKI), but the mortality rate associated with this treatment remains high, and the risk factors for mortality have yet to be identified. This study explored the independent risk factors for 28-day mortality among elderly patients receiving CRRT.

methodsThis retrospective study included clinical data from 144 elderly (≥ 60 years old) critically ill AKI patients in the intensive care unit (ICU) who received CRRT at Jinqiu Hospital in Liaoning Province from December 2015 to December 2024. Baseline characteristics, laboratory indicators 24 h before CRRT and Sequential Organ Failure Assessment (SOFA) scores were recorded. Cox regression analysis was used to analyze the risk factors for all-cause mortality within 28 days.

resultsThe 28-day mortality rate of elderly critically ill patients was 50%. Multivariate Cox regression analysis revealed that elevated lactate levels (HR = 1.167, 95% CI 1.061–1.283; P = 0.001) and elevated SOFA scores (HR = 1.152, 95% CI 1.045–1.269; P = 0.005) were independent risk factors for 28-day mortality.

conclusionThe SOFA score and elevated lactate level were found to be independent predictors of 28-day mortality among elderly critically ill AKI patients who underwent CRRT. Additional studies with larger sample sizes are needed to validate these results.

Indexed as

Acute Kidney InjuryContinuous Renal Replacement TherapyCritical IllnessAgedAged, 80 and overChinaFemaleHumansIntensive Care UnitsMaleMiddle AgedOrgan Dysfunction ScoresRetrospective StudiesRisk FactorsAcute kidney injuryElderly patientsRenal replacement therapyRisk factors

Identifiers

PMID41402766
PMCPMC12709745

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.